Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07540910 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT07540910: Recruiting Phase 1 study, sponsored by Enanta Pharmaceuticals.
NCT07540910 is a Phase 1 study that is actively recruiting participants, run by Enanta Pharmaceuticals. The registered enrollment target is 98 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07540910, a Phase 1 study, is actively recruiting participants, sponsored by Enanta Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG EDP-978
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What NCT07540910 shows while recruiting
NCT07540910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07540910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07540910 about?
NCT07540910 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults". This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in healthy adult subjects.
What is the current status of trial NCT07540910?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2026-04-01. Estimated completion is 2026-11.
What interventions are being tested in trial NCT07540910?
The interventions under investigation include: Placebo (DRUG), EDP-978 (DRUG).
Who is sponsoring clinical trial NCT07540910?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07540910's enrollment target sits among peer trials
98 592nd of 2000 higher than 1,404 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI